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Mechanisms	of	Ad5-Induced	Immune	Dysfunction	
Abstract	
The	failure	of	an	Adenovirus	5	(Ad5)-based	human	immunodeficiency	virus	type	1	(HIV-1)	
vaccine	in	the	STEP	trial	warranted	a	detailed	evaluation	of	the	immunological	properties	of	
Ad5.	Previous	studies	have	revealed	that	immunization	with	Ad5	induces	a	partially	exhausted	T	
cell	response	but	the	mechanism	of	Ad5-induced	immune	dysfunction	is	unknown.		Using	
classical	animal	models,	it	has	been	shown	that	altering	antigen	dose,	and	modulating	the	PD-
1/PD-L1	signaling	pathway,	or	modulating	regulatory	T	cells	(Tregs)	can	influence	the	quality	of	
memory	CD8	T	cell.	Therefore,	we	interrogated	whether	these	factors	play	similar	roles	in	Ad5-
induced	dysfunction.	Here,	we	show	that	reducing	Ad5	vaccine	dose	induces	highly	functional	
memory	CD8	T	cell	responses,	characterized	by	lower	PD-1	expression,	higher	cytokine	co-
expression,	and	an	improved	recall	expansion	following	a	heterologous	boost.	Interestingly,	we	
show	that	the	dysfunctional	recall	of	Ad5-primed	T	cells	following	high-dose	immunization	may	
partly	be	mediated	by	a	PD-1-dependent	CD8	T	cell	intrinsic	phenomenon,	as	blockade	of	PD-L1	
leads	to	a	substantial	improvement	in	anamnestic	T	cell	expansion.		Furthermore,	we	provide	
preliminary	data	suggesting	that	Treg	may	not	play	a	crucial	role	in	the	development	of	Ad5-
induced	dysfunction.	Overall,	our	data	contribute	to	the	understanding	of	the	mechanism	of	
Ad5-induced	immune	dysfunction,	and	may	be	relevant	for	improving	vaccination	modalities	
for	HIV	and	other	chronic	viral	infection.	
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1. Chapter	1:	Background	
1.1 Introduction	
Vaccines	are	one	of	the	most	important	public	health	tools	in	the	fight	against	infectious	
diseases.	The	goal	of	vaccines	is	to	generate	long-lived	immunological	protection,	with		memory	
immune	response	that	can	prevent	natural	infection	or	significantly	lessen	the	disease	burden1.	
Most	of	the	currently	licensed	vaccines	have	primarily	conferred	this	immunological	protection	
via	the	induction	of	high-affinity	neutralizing	antibodies.	However,	developing	highly	effective	
vaccines	against	intracellular	pathogens	such	as	human	immunodeficiency	virus-1	(HIV-1),	
Mycobacterium	tuberculosis,	Plasmodium	falciparum,	hepatitis	C	virus	(HCV)	will	also	require	
the	generation	of	potent	memory	CD8	T	cells2,	3,	4,	5,	6.	In	order	to	elicit	a	potent	cellular	immune	
response,	the	vaccine	antigen	must	be	processed	endogenously	within	antigen	presenting	cells	
and	presented	in	the	context	of	class	I	major	histocompatibility	complex	(MHC-I)	molecules	to	
CD8	T	cells.	Until	recently,	achieving	this	goal	has	been	hampered	by	a	lack	of	vaccine	platforms	
capable	of	such,	which	has	led	to	the	development	of	novel	platforms	including	DNA	vaccines	
and	viral	vectors.		
DNA	vaccines	are	genetically	engineered	plasmids	containing	the	DNA	sequence	of	the	
antigen	of	interest	that	can	be	delivered	directly	into	the	appropriate	tissue7.	DNA	vaccines	are	
safe	and	capable	of	eliciting	protective	cellular	and	humoral	immune	responses	in	small	animal	
models8,	9.	However,	their	application	is	limited	by	their	low	immunogenicity	in	human	and	
other	primates9.	The	suboptimal	immunogenicity	of	DNA	vaccines	in	primates	may	partly	be	
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due	to	binding	of	the	DNA	to	serum	amyloid	P	component	(SAP),	a	negative	regulator	of	the	
innate	immune	response10.	The	limited	efficacy	DNA	vaccines	led	to	the	development	of	more	
immunogenic	viral	vector	vaccines.		
In	contrast	to	DNA	vaccines,	viral	vectors	have	been	shown	to	be	highly	immunogenic,	both	
in	preclinical	and	clinical	studies11.	They	are	typically	attenuated	viruses	that	are	genetically	
modified	to	carry	an	antigen	to	which	an	immune	response	is	being	sought	into	the	body.	They	
also	elicit	very	potent	innate	immune	responses	through	the	binding	of	specific	Toll-like	
receptors	(TLRs)	leading	to	the	generation	of	a	cytokine	milieu	which	modulate	the	adaptive	
immune	response12.	The	adaptive	immune	response	induced	by	these	vectors	differ	
quantitatively	and	qualitatively	based	on	the	distinct	biological	properties	of	the	vector.	Over	
the	last	couple	of	years,	a	wide	range	of	virus	families	have	been	developed	and	tested	as	
vaccine	vectors	for	either	human	or	veterinary	use11,	13,	14,	15.	Among	these	wide	array	of	viruses	
which	include	canarypox	virus16,	flavivirus17,	lentivirus18,	modified	vaccinia	virus	Ankara19	and	
sendai	virus20,	adenovirus21	has	been	the	most	widely	studied	replication-defective	vaccine	
vectors.	Of	all	the	adenovirus	serotypes	isolated	so	far,	adenovirus	5	(Ad5)	is	the	best	
characterized22.		
However,	following	the	failure	of	an	Ad5-based	HIV	vaccine	in	clinical	trials,	a	detailed	
evaluation	of	the	immunological	properties	revealed	that	it	elicited	a	dysfunctional	immune	
response23.	It	has	been	suggested	that	this	dysfunctional	response,	coupled	with	the	prevalent	
pre-existing	Ad5-vector	immunity	may	have	contributed	to	the	failure	of	the	Ad5-based	
vaccine.	However,	the	possible	biological	or	immunological	parameters	responsible	for	the	
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immune	dysfunction	is	not	fully	understood.		Although	there	are	ongoing	pre-clinical	and	
clinical	studies	evaluating	the	immunogenicity	and	protective	efficacy	of	other	serotypes	of	
adenoviruses12,	understanding	the	biological	and	immunological	properties	of	Ad5	that	may	
have	contributed	to	the	dysfunctional	T	cell	response	will	help	in	the	selection	of	novel	vaccine	
vectors,	some	of	which	are	phylogenetically	related	to	Ad5.			
	
1.2 Adenovirus	Biology		
Adenoviruses	are	a	family	of	airborne	viruses	that	infect	virtually	all	major	classes	of	
vertebrates	causing	mild	to	severe	diseases	of	the	airways	and	gastrointestinal	tracts24.	
Currently,	more	than	60	distinct	adenovirus	serotypes	of	human	origin	have	been	identified25.	
These	viruses	are	subdivided	into	seven	different	serotypes	(subgroups	A	through	G)	based	on	
the	neutralizing	antibodies	profiles	and	this	corresponds	to	the	divergence	of	nucleotide	
sequence	of	the	capsid	protein	genes25.		
Adenoviruses	are	double	stranded	DNA	viruses	with	a	non-enveloped	icosahedral	shell,	70-
100	nm	in	diameter,	enclosing	about	~26-43	kilobases	long	linear	genomic	material26.	The	
genome	is	made	up	of	early	and	late	genes,	classified	based	on	the	time	of	expression	in	
relation	to	DNA	replication.	The	early	genes	(E1a,	E1b,	E2a,	E2b,	E3,	and	E4)	express	proteins	
before	DNA	replication	and	they	are	involved	in	activating	and	modulating	transcription,	the	
cell-cycle,	cell	signaling,	DNA	repair	and	immune	evasion27,	28,	29.	The	late	genes	(L1–L5)	which	
are	expressed	following	DNA	replication,	code	mostly	for	structural	protein30.	E1,	E2,	and	E4	
gene	products	regulate	transcription	of	late	genes	while	E3	gene	products	subvert	the	host	
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immune	response	by	affecting	the	intracellular	trafficking	machinery,	preventing	antigen	
presentation	and	modulating	cytokine	pathways31.	Genetic	manipulation	of	these	early	genes	is	
often	employed	in	order	to	adapt	adenovirus	for	use	as	vectors	
Structurally,	the	adenovirus	capsid	is	icosahedral,	with	each	icosahedron	containing	12	
copies	of	hexon	trimers	and	a	pentameric	pentons	located	at	the	12	vertices32.	Projecting	from	
the	penton	bases	are	trimeric	fibers	which	are	made	up	of	a	distal	knob	domain,	a	shaft,	and	an	
N-terminal	tail32.	The	distal	knob	domain	of	the	fibers	selectively	binds	with	high	affinity	to	
cellular	receptors,	leading	to	cellular	transduction.	Entry	receptors	identified	so	far	include	
coxsackievirus	B	and	adenovirus	receptor	(CAR),	CD46,	sialic	acids,	desmoglein	2,	and	
CD80/8633,	34,	35,	36,	37,	38.	The	most	characterized	include	the	coxsackievirus	B	and	adenovirus	
receptor	(CAR),	which	is	expressed	mainly	on	epithelial	and	endothelial	cells	in	human,	non-
human	primates	and	mice	34;	and	CD46,	a	regulatory	protein	in	the	complement	system	that	is	
expressed	on	most	cells	in	humans,	yet	restricted	to	the	testis	and	sperm	in	mice39.	
Adenoviruses	belonging	to	serotypes	A,	C,	D,	E,	and	F	uses	CAR	for	cellular	attachment	while	
CD46	is	used	by	the	adenoviruses	in	serotypes	B	and	D40.	In	addition	to	the	difference	in	
receptor	usage,	adenoviruses	also	differ	in	their	intracellular	trafficking	characteristics	and	
association	with	the	nuclear	envelope,	with	some	exiting	the	endosomal	space	rapidly	following	
endocytosis	and	translocating	immediately	to	the	nucleus	(subgroup	C)	while	others	traffic	to	
the	late	endosome	and	therefore	exhibit	a	slower	association	with	the	nucleus	(subgroups	B	
and	D)41,	42,	43,	44.	The	differences	in	cellular	receptor	and	intracellular	trafficking	influence	
cellular	tropism,	particularly	the	immune	cell	subsets	these	viruses	interact	with,	the	pattern	
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recognition	receptors	(PRRs)	they	activate,	the	specific	tissue	sites	where	the	transgene	are	
expressed,	and	therefore	the	characteristics	of	innate	and	adaptive	immune	response	activated	
by	these	viruses.	Appreciation	of	how	these	properties	influence	the	immune	response	is	
particularly	important	when	adenoviruses	are	used	as	vaccine	vectors.		
1.3 Adenovirus	as	a	Vaccine	Vector	
Following	their	discovery	over	six	decades	ago45,	adenoviruses	have	evolved	to	be	an	
important	biological	tool	utilized	as	model	system	providing	significant	insights	into	complex	
cellular	processes	such	as	DNA	replication	and	transcription,	DNA	repair	responses,	oncogenesis	
and	alternate	RNA	splicing46,	47.	Additionally,	their	ability	to	readily	infect	human	and	other	
mammalian	cells	have	made	them	a	popular	choice	for	gene	delivery48.	Their	application	in	
gene	therapy	was	however	hindered	by	the	robust	immune	response	they	induce	leading	to	a	
shortened	duration	of	transgene	expression49.	Interestingly,	this	strong	immunogenicity	has	
been	exploited	by	vaccinologists	with	the	development	of	many	adenoviral	vaccine	vectors.	
Adenoviruses	have	some	unique	features	that	make	them	particularly	suitable	for	use	as	
vaccine	vectors12,	22.	First,	they	have	a	very	broad	cellular	tropism	with	the	ability	to	infect	and	
express	its	transgene	in	a	wide	variety	of	rapidly	dividing	and	non-dividing	cells.	Secondly,	they	
are	stable	and	can	be	readily	grown	and	purified	in	large	quantities.	Thirdly,	they	cause	
relatively	mild	disease	in	human	and	compared	to	lentiviral	vectors,	they	do	not	integrate	into	
the	host	cell	genome,	reducing	the	risk	of	malignant	transformation.	Fourthly,	their	genome	is	
well	characterized	and	can	be	easily	manipulated	to	render	them	replication-defective.	This	is	
typically	achieved	by	deleting	the	early	gene	E1,	which	is	required	for	adenovirus	replication.	In	
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addition,	E3,	another	early	gene	important	for	host-vector	immune	interaction,	is	often	
deleted.	Although	not	essential	in	E1-deleted	adenovirus,	deletion	of	E3	or	E3/E4	regions	offers	
the	benefit	of	increasing	the	transgene	insertion	capacity	to	up	to	7.5kbp	to	carry	medium-sized	
protein	transgenes50,	51.	Furthermore,	vectorized	adenoviruses	are	thermostable	and	have	been	
demonstrated	in	both	preclinical	and	clinical	studies	to	be	safe	for	both	systemic	and	mucosal	
surface	application22.	Finally,	and	most	importantly,	replication	incompetent	adenoviruses	are	
highly	immunogenic,	inducing	robust	antibody	and	cell-mediated	immunity	to	the	inserted	
transgenes	with	the	ability	to	elicit	both	systemic	and	mucosal	immune	response	following	
parenteral	delivery52,	53,	54.		
	
1.4 Human	Adenovirus	5	Vaccine	Vector	
Ad5	is	the	most	studied	of	the	adenovirus	vectors.	It	is	a	serotype	C	virus	and	transduces	
cells	either	through	the	use	of	the	coxsackie-adenovirus	receptor	(CAR)34	or	in	a	CAR-
independent	pathway55.	As	a	stand	alone	vaccine	vector,	it	is	arguably	the	most	immunogenic	
human	adenovirus	serotype.		Ballay	A.	et	al	was	the	first	to	report	that	recombinant	
replication–competent	Ad5	carrying	hepatitis	B	surface	elicits	antibody	response	against	the	
transgene	in	rabbits51.	Not	long	afterwards,	the	ability	of		E1-deleted	replication-incompetent	
Ad5	vectors	expressing	rabies	virus	glycopeptide	(GP)	to	induce	protective	titers	of	neutralizing	
antibodies	and	rabies-virus	specific	CD8	and	CD4	T	cells	was	demonstrated56.	Following	this	
important	finding,	replication-incompetent	Ad5	has	been	tested	in	several	other	preclinical	and	
clinical	studies	and	shown	to	elicit	both	neutralizing	antibodies	and	cellular	immune	responses	
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against	pathogens	such	as	dengue	virus,	ebola	virus,	hepatitis	C	virus,	Epstein-Barr	virus,	
Streptococcus	pneumonia,	Mycobacteria	tuberculosis,	Plasmodium	falciparum,		HIV	among	
others57,	58,	59,	60,	61,	62,	63.			
In	the	HIV	field,	Ad5	expressing	simian	immunodeficiency	virus	(SIV)	Gag	peptide	conferred	
a	protective	immune	response	following	challenge	of	rhesus	monkeys	with	pathogenic	SIV/HIV	
chimera	SHIV	89.6P10,	but	failed	to	protect	against	a	more	stringent,	neutralization-resistant	
strain	SIVmac23964,	65.	Subsequently,	two	large	Phase	IIb	clinical	trials	(STEP	in	North	America	
and	Phambili	trials	in	South	Africa)	were	commenced66,	67.	In	these	studies,	the	Merck	Ad5-Gag-
Pol-Nef	vaccine	was	administered	three	times	to	volunteers	that	had	either	none	or	moderate-
to-high	titers	of	neutralizing	antibodies	against	Ad5	with	the	aim	of	eliciting	HIV-specific	T-cell	
responses	capable	of	providing	complete	or	partial	protection	from	HIV-1	infection	or	a	
decrease	in	viral	load	set	points	post-infection.	Both	studies	were	stopped	and	unblinded	
before	completion	of	enrollment	following	an	interim	analysis	of	the	STEP	trial	that	showed	a	
lack	of	efficacy67.	Even	more	alarming	was	a	subsequent	analysis	that	revealed	a	trend	toward	
higher	HIV-1	acquisition	in	vaccine	recipients	compared	to	placebo	controls,	particularly	in	a	
subgroup	of	uncircumcised	men	with	high	baseline	Ad5	seropositivity67.	Although	not	
completely	proven,	a	probable	explanation	for	this	unexpected	finding	is	that	the	vaccine	led	to	
an	increase	in	the	number	of	HIV-1	target	cells,	resulting	from	the	activation	of	Ad5-specific	
CD4	T	cells	at	mucosal	surfaces68,	69.		Furthermore,	a	second	Ad5-based	Phase	IIb	HIV	vaccine	
clinical	trial	(HVTN	505)	did	not	show	protective	efficacy	against	HIV-1	infection	in	human70.	It	is	
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important	to	note	however,	that	the	Ad5	used	in	this	study	was	different	in	design	from	the	
Merck	Ad5	vector,	and	was	used	as	a	boosting	vector	following	a	DNA	vaccine	prime.		
The	failure	of	the	Ad5	vector	in	these	clinical	trials	led	to	a	renewed	interest	in	two	areas	of	
Ad	vector	research.	First	is	the	development	and	evaluation	of	rarer	adenovirus	serotypes	of	
human	origin50,	71,	as	well	as	serotypes	derived	from	other	species	such	as	chimpanzees72,	73,	74	
and	rhesus	monkeys75,	and	structurally	modified	Ad5	vector	expressing	heterologous	
adenovirus	hexons76	in	order	to	circumvent	the	problem	of	pre-existing	Ad5	vector	immunity.	
The	other	area	of	intense	research	is	the	analysis	of	the	biologic	properties	of	Ad	vector-
induced	immune	responses23,	77,	78,	79,	80,	81,	82.	These	detailed	analyses	have	shed	more	light	on	
the	inherent	properties	of	Ad5-induced	T	cell	responses,	highlighting	how	these	responses	
substantially	differ	from	those	elicited	by	alternative	serotype	Ad	vector	such	as	adenovirus	26	
(Ad26)	or	adenovirus	35	(Ad35).		
	
1.5 Ad5-induced	Immune	Dysfunction	
The	most	surprising	finding	from	the	comprehensive	evaluation	of	the	phenotype	and	
quality	of	Ad	vector-induced	immune	response	was	that	Ad5,	compared	to	other	serotype	
adenoviruses,	induces	a	partially	impaired	immune	response.	This		observation	was	first	
reported	by	Yang	et	al	when	they	analyzed	the	phenotypic	profile	of	the	immune	responses	
elicited	by	an	Ad5	vaccine	in	mice83.	They	observed	that	Ad5-elicited	CD8	T	cells	exhibit	a	
protracted	effector	phenotype	with	a	delayed	contraction	phase,	a	phenomenon	they	argued	
may	be	due	to	the	prolonged	antigen	presentation	seen	following	Ad5	immunization83.	In	line	
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with	this	observation,	others	have	shown	that,	compared	to	alternative	serotype	Ad	vectors,	
Ad5	induces	a	partially	dysfunctional	T	cell	response	in	mice.	Ad5-induced	memory	T	cells	were	
found	to	express	low	levels	of	IL-7	alpha	chain	receptor	CD127,		lymphoid	homing	receptor	
CD62L,	antiapoptotic	molecule	Bcl-2,	as	well	as	high	levels	of	inhibitory	receptors	PD-1	and	Tim	
323,	81,	82,	84.	Although	Ad5	immunization	induces	a	high	magnitude	primary	T	cell	response,	
these	T	cells	are	less	polyfunctional	with	reduced	capability	to	secrete	IFN-γ,	TNF-α,	and	IL-2,	
compared	to	alternative	serotype	adenovirus23,	82.	Furthermore,	circulating	and	tissue	resident	
antigen-specific	memory	CD8	T	cells	induced	by	Ad5	proliferate	less	robustly	following	a	
secondary	exposure	(boosting)	to	antigens81.	Similar	findings	have	also	been	observed	in	non-
human	primates79.	It	is	important	to	note	that	although	recombinant	E1-deleted	Ad5	vector	
does	not	replicate,	it	induces	a	memory	CD8	T	cell	population	that	to	some	extent	–	except	for	
its	functionality	–	is	reminiscent	of	an	exhausted	T	cell	response	seen	in	models	of	chronic	
infection	or	cancer	characterized	by	persistent	antigenic	stimulation85,	and	as	such	suggests	
that	Ad5-induced	CD8	T	cells	may	be	“partially	exhausted”	(Table	A).		
	
1.6 Factors	Influencing	Ad5-induced	Immune	Dysfunction	
In	order	to	understand	why	Ad5-induced	memory	CD8	T	cells	exhibit	such	dysfunctional	or	
“partially	exhausted”	phenotypes,	it	is	I		tt	mportant	to	consider	the	virological	and	
immunological	cues	that	influence	the	development	and	maintenance	of	exhausted	CD8	T	cells	
in	the	classical	immune	exhaustion	model	of	chronic	infection,	and	assess	whether	these	
factors	play	similar	roles	in	mediating	Ad5-induced	immune	dysfunction,	and	more	importantly,	
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if	modulation	of	these	parameters	will	lead	to	an	improvement	in	the	phenotype	and	quality	of	
Ad5-induced	memory	CD8	T	cells.		Extrapolating	from	this	classical	model	and	relying	on	our	
current	understanding	of	the	biology	of	Ad5,	possible	factors	that	may	favor	the	development	
of	Ad5-induced	immune	dysfunction	include	1)	vector	dose,	2)	immuno-inhibitory	receptors,	3)	
CD4	T	cells	-	conventional	and	regulatory	T	cells	and	4)	antigen	presenting	cells	and	expression	
of	co-stimulatory	and/or	co-inhibitory	molecules.	(Figure.	A).	
	
1.6.1 Vector	Dose	
The	amount	and	duration	of	antigen	exposure	impact	antigen-specific	CD8	T	cells	both	
in	terms	of	quantity	and	quality.	In	an	acute	infection	model,	antigen	dose	affects	the	number	
of	naïve	CD8	T	cells	recruited	for	activation	and	their	differentiation	into	effector	and	memory	
CD8	T	cells86.	While	in	chronic	infections,	such	as	the	chronic	model	of	lymphocytic	
choriomeningitis	virus	(LCMV)	infection	in	mice,	differentiation	of	primed	CD8	T	cells	into	either	
an	exhausted	or	memory	phenotype	is	dependent	on	the	amount	and	duration	of	antigen	
exposure87,	88.	Likewise,	in	Ad	vector	vaccine	research,	the	dose	of	Ad	vector	impacts	the	quality	
of	transgene-specific	CD8	T	cell	differentiation	and	functionality78.	High	dose	Ad5	immunization	
has	been	shown	to	induce	transgene	specific	CD8	T	cells	bearing	features	of	a	dysfunctional	T	
cell	population:	reduced	functional	CD8	T	cells	as	evidenced	by	lower	per	cell	expression	of	IFN-
γ,	lower	fraction	of	cells	coproducing	TNF-α	or	IL-2	and	IFN-γ;	impaired	memory	conversion	
with	lower	expression	of	CD127	and	high	expression	of	KLRG-1;	and	an	absence	of	a	contraction	
phase78,	89.	Conversely,	reducing	the	dose	of	Ad5	significantly	improves	some	of	these	
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impairments78.	However,	the	effect	of	lowering	the	priming	dose	of	Ad5	on	recall	expansion	
following	antigen	re-exposure	has	not	been	investigated	to	date.	In	addition,	it	is	also	not	
known	whether	lowering	the	dose	will	lead	to	a	reduced	expression	of	immunoinhibitory	
receptors,	suggesting	a	reduced	immune	exhaustion.		
	
1.6.2 Immunoinhibitory	Receptors	
Immunoinhibitory	receptors	such	as	PD-1	(Programmed	Cell	Death	1),	Tim-3	(T-cell	
immunoglobulin	and	mucin-domain	containing-3),	and	2B4	(CD244)	are	induced	on	T	cells	
immediately	following	activation,	and	at	this	stage,	they	serve	as	safeguards	to	curtail	excessive	
immune	response23,	85.	However,	the	sustained	up-regulation	of	immunoinhibitory	receptors	
has	been	recognized	as	a	prominent	feature	of	exhausted	CD8	T	cells,	where	they	play	a	
significant	role	in	negatively	regulating	T	cell	function90.	The	most	widely	studied	of	these	
receptors	is	PD-1,	a	member	of	the	CD28	superfamily,	which	is	inducibly	expressed	on	T	cells,	B	
cells,	natural	killer	T	(NKT)		cells,	and	some	myeloid	cells91.	Like	other	members	of	the	family,	
PD-1	transduces	signals	only	in	the	context	of	T	cell	receptor	(TCR)	crosslinking	following	a	TCR-
antigen-MHC	engagement.	PD-1	has	two	ligands:	PD-L1	and	PD-L2.	PD-L1,	also	known	as	B7-H1,	
has	a	broad	tissue	distribution	and	is	expressed	on	B	cells,	DCs,	macrophages,	BM-derived	mast	
cells,	and	T	cells	and	peripheral	epithelial	and	endothelial	cells	upon	stimulation	by	
proinflammatory	cytokines,	such	as	interferons	and	tumor	necrosis	factor92,	93,	94.	PD-L2	or	B7-
DC	is	more	restrictively	expressed	on	dendritic	cells	and	macrophages	93.	Upon	interaction	with	
its	ligands,	PD-1	sends	signals	that	limit	proliferation,	interfere	with	cytotoxic	activity	and	IFN-γ	
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production	through	the	up-regulation	of	the	transcription	factor	BATF	in	CD8	T	cells95,	96.	The	
suppressive	function	of	PD-1	is	also	achieved	via	the	reduction	in	the	duration	of	DC:T	cell	
contact,	and	the	direct	dephosphorylation	of	proximal	TCR	signaling	through	the	recruitment	of	
SHP1	and	SHP2	phosphatases	by	the	immunoreceptor	tyrosine-based	switch	(ITSM)	motif	on	
the	intracellular	cytoplasmic	tail	of	the	PD-1	receptor97,	98,	99.	Other	immunoinhibitory	receptors	
that	are	up-regulated	on	exhausted	T	cells	include	CTLA4,	Tim-3,	LAG-2,	CD160	and	2B4	and	
these	receptors	have	been	shown	to	act	either	independently	or	in	synergy	with	one	another	
and/or	with	PD-1	to	influence	the	degree	of	T	cell	exhaustion85.		Partial	restoration	of	T	cell	
function	can	be	achieved	by	blocking	the	signaling	pathways	of	these	receptors	(known	as	
immune	checkpoint	blockade)100.		
As	mentioned	earlier,	Ad5	vector	elicited	greater	percentages	of	transgene-specific	CD8	
T	cells	co-expressing	both	PD-1	and	Tim-3	or	singly-positive	for	either	PD-1	or	Tim-3	23	
(Penaloza-MacMaster,	P.	et	al.	unpublished	data).	Indeed,	PD-1	and	Tim-3	expression	on	Ad5-
induced	T	cells	is	associated	with	less	functionality	(Penaloza-MacMaster,	P.	et	al,	unpublished	
data)	similar	to	findings	in	the	chronic	model	of	LCMV	infection	in	mice85	or	HIV	infection	in	
humans101.	Additionally,	the	higher	co-expression	of	PD-1	and	Tim-3	correlates	with	reduced	
levels	of	memory	markers	on	CD8	T	cells,	possibly	explaining	the	poor	anamnestic	potential	
seen	with	Ad5	immunization.	Similarly,	increased	PD-1	expression	was	also	observed	on	
“helpless”	memory	CD8	T	cells	compared	to	memory	CD8	T	cells	primed	in	the	presence	of	CD4	
T	cells102.	Interestingly,	PD-1	blockade	during	antigen	re-exposure	enhanced	expansion	of	these	
‘helpless’	memory	CD8	T	cells102,	indicating	that	PD-1	may	limit	memory	CD8	T	cell	expansion.	
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Furthermore,	PD-1	blockade	has	been	shown	to	restore	pulmonary	CD8	T	effector	functions	
(degranulation	and	cytokine	production)	and	enhanced	viral	clearance	in	a	model	of	respiratory	
virus	reinfection103.	It	is	not	known	whether	a	similar	improved	recall	expansion	and	restoration	
of	polyfunctionality	will	be	seen	following	checkpoint	blockade	in	the	context	of	Ad5	
immunization.		
	
1.6.3 Conventional	and	Regulatory	CD4	T	cells	
It	is	well	established	that	conventional	CD4	T	cell	help	is	required	for	memory	CD8	T	cell	
differentiation	following	natural	infection104,	105	or	vaccination106.	It	has	been	reported	that	Ad5	
induces	a	dysfunctional	CD4	T	cell	response	characterized	by	high	PD-1	expression	and	IL-10	
expression80,	while	an	alternative	serotype	adenovirus,	Ad26,	which	induces	a	more	favorable	
CD8	T	cell	response	with	better	phenotypic	and	qualitative	profile	efficiently	elicits	functional	
CD4	T	response79.	The	impaired	CD4	T	cell	help	associated	with	Ad5	may	therefore	be	
responsible	for	Ad5-induced	CD8	T	cell	dysfunction.	On	the	other	hand,	regulatory	CD4	T	cells	
(Tregs),	whose	primary	role	is	to	control	and	dampen	immune	response,		have	been	shown	to	
help	in	maintaining	CD8	T	cell	exhaustion,	and	the	ablation	of	Tregs	in	mice	chronically	infected	
with	LCMV	led	to	a	significant	rescue	and	expansion	of	exhausted	LCMV-specific	CD8	T	cells107.	
Since	Ad5-induced	immune	dysfunction	exhibits	some	exhausted	T	cell	phenotype,	it	is	not	
impossible	that	regulatory	T	cells	may	play	a	role	in	driving	this	exhaustion.	This	is	however	yet	
to	be	determined.			
	
		
14	
1.6.4 Antigen	Presenting	Cells,	Co-stimulatory	and	Co-inhibitory	Molecules	
Adenoviral	vectors	differentially	interact	with	antigen	presenting	cells	(APCs)	such	as	
dendritic	cells	(DCs)55	due	to	their	distinct	in	vivo	biological	properties108,	109.	It	has	been	shown	
that	Ad	vectors	form	immune	complexes	with	specific	neutralizing	antibodies	which	affect	
transduction	efficiency	and	maturation	of	dendritic	cells	in	a	FcR	and	Toll-like	receptor	9	(TLR9)	
interaction68.	Comparative	evaluation	of	the	potency	of	immune	complexes	formed	by	Ad5	and	
alternative	serotype	adenovirus	vectors	such	as	Ad26	and	Ad36	showed	that	immune	
complexes	of	Ad5	were	stronger	inducers	of	DC	maturation	(as	measured	by	the	up-regulation	
of	co-stimulatory	molecules	and	production	of	proinflammatory	cytokines)	compared	to	Ad26	
and	Ad35	immune	complexes68.	It	is	however	not	known	if	the	stronger	DC	induction	combined	
with	the	more	protracted	persistence	of	Ad5	influences	the	impaired	immune	response	seen	in	
Ad5.	The	role	of	co-stimulatory	(e.g.	B7-1)	and	co-inhibitory	molecules	(e.g.	PD-L1)	expressed	
on	antigen	presenting	cells	following	Ad	vector	transduction	and	how	they	may	contribute	to	
the	impaired	immune	response	is	not	fully	understood.	
	
1.7 Summary	
Vaccine-mediated	protection	against	intracellular	infections	such	as	HIV-1,	malaria	and	
tuberculosis	will	most	likely	require	the	generation	of	potent	humoral	and	cellular	immune	
responses.	Until	its	failure	in	the	HIV-1	vaccine	trial	(STEP	trial),	Ad5	was	one	of	the	most	
promising	vectors	used	for	eliciting	such	responses.	Evidence	is	accumulating	that	the	immune	
response	elicited	by	Ad5-based	vaccine	vectors	exhibits	a	dysfunctional	phenotype,	and	that	
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this	dysfunction	may	have	contributed	to	its	failure.	Assessing	the	immunological	and	biological	
cues	that	affect	a	similarly	impaired	T	cell	response	in	the	chronic	viral	infection	(LCMV)	model	
may	help	us	elucidate	the	mechanism	of	Ad5-induced	immune	dysfunction.	
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1.8 Figures	
1.8.1 Figure	A:	Potential	factors	influencing	Ad5-induced	immune	dysfunction		
	
	
	
A	schematic	representation	of	the	possible	factors	influencing	the	development	and	
maintenance	of	Ad5-induced	immune	dysfunction	
	
	
	
	
	
	
Ad5-induced	
immune	
dysfunction
Virological	factors:
Vector	dose
Route	of	Administration
Cellular	tropism
CD8	T	cell	intrinsic:
Immunoinhibitory
receptors
Epigenetic	modifiers
CD8	T	cell	extrinsic:
Impaired	CD4 help
Regulatory	T	cells
APCs	+	co-stimulatory	and	
co-inhibitory	molecules
Cytokine	milieu
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Table	A:	Spectrum	of	exhausted	CD8	T	states	
	
	
	
	
Fully	Functional	
Memory	CD8	T	
cells	(e.g.		Acute	
LCMV	infection,	
Ad26-Induced	
memory	CD8	T	
cells)	
	
	
Ad5-induced	
memory	CD8	T	
cells	
	
	
	
Partially	exhausted	
CD8	T	cells	(e.g.	
Early	chronic	LCMV	
infection)	
	
	
	
Severely	
Exhausted	CD8	T	
cell	(e.g.	Late	
Chronic	LCMV	
infection)		
Antigen	load	 --	 ?-/+	 ++	 ++++	
CD4	help	 +++	 ?++	 ++	 ---	
IL-2	 ++	 -	 -	 -	
TNF-α	 +++	 ++/-	 +/-	 -	
IFN-y	 +++	 ++	 ++	 -	
Cytotoxicity	 +++	 ++	 +	 -	
Inhibitory	
Receptors	 +	 ++	 ++	 +++	
Proliferative	
Potential	 +++	 +	 +	 -	
Apoptosis	 -	 -	 +/-	 ++++	
	
Classical	immune	exhaustion	in	chronic	infections	and	cancers	is	characterized	by	a	step-wise	and	
progressive	loss	of	effector	capabilities,	the	sustained	upregulation	of	inhibitory	receptors,	and	
the	 loss	 of	 self-renewal	 capabilities.	 Ad5-elicited	 CD8	 T	 cells	 lie	 in	 a	 spectrum	 between	 fully	
functional	memory	CD8	T	cells	generated	following	the	clearance	of	an	acute	infection	(e.g.	Acute	
LCMV	infection	or	alternative	serotype	adenoviral	(e.g.	Ad26)	immunization)	and	fully	exhausted	
CD8	T	cells	from	chronic	LCMV	infection.	The	role	of	vector	load/persistence	and	CD4	T	cell	help	
in	modulating	Ad5-induced	immune	exhaustion	has	not	yet	been	fully	determined.	(Adapted	and	
modified	from	Kahan	SM	et	al.		Virology.	201385)	
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2. Chapter	2:	Data	and	Methods	
2.1 Introduction		
Replication-incompetent	human	adenovirus	serotype	5	(Ad5)	vector	elicits	potent	and	
protective	CD8+	T	cell	responses	in	preclinical	studies.	However,	a	detailed	evaluation	of	the	
immunological	properties	of	Ad5	in	mouse	and	non-human	primates	has	revealed	that	Ad5	
elicits	a	partially	exhausted	T	cell	response,	characterized	by	low	frequency	of	polyfunctional	T	
cells,	high	expression	of	immunoinhibitory	receptors,	dysfunctional	cytokine	secretion,	and	an	
impaired	memory	recall.	Recently,	it	has	been	shown	that	factors	such	as	vector	priming	dose	
or	antigen	load,	expression	of	immunoinhibitory	receptors,	and	regulatory	T	cells	may	modulate	
the	phenotype,	quality	and	anamnestic	potential	of	memory	T	cells.	In	this	study,	we	
investigated	the	possible	role	of	vector	dose,	PD-1	signaling	pathway,	and	regulatory	T	cells	in	
modulating	Ad5-induced	cellular	immune	response.		
2.1.1 Hypothesis	
Vector	dose,	PD-1	signaling	and	regulatory	T	cells	modulate	Ad5-induced	cellular	
immune	response.	
2.1.2 Specific	research	questions:	
1. Is	it	possible	to	overcome	the	impaired	anamnestic	immune	response	associated	with	Ad5	
by	altering	the	priming	dose?	
2. What	is	the	effect	of	immunoinhibitory	receptor	blockade	on	the	recall	of	Ad5-induced	
memory	CD8	T	cells?	
3. Is	there	a	role	for	regulatory	T	cells	in	modulating	the	Ad5-elicited	immune	dysfunction?	
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2.2 Materials	and	Methods	
2.2.1 Mice	and	immunizations	
Six	to	8-week-old	female	C57BL/6	mice	(from	Jackson	Laboratories)	were	used	for	all	
immunization	experiments.	Replication-incompetent,	E1/E3-deleted	Ad5,	Ad26	and	Ad35	
vectors	expressing	SIVmac239	Gag	were	prepared	as	previously	described71,	110,	while	modified	
vaccinia	Ankara	(MVA)	expressing	SIV	Gag-Pol-Env	was	prepared	by	the	National	Institutes	of	
Health	(NIH).	Mice	were	immunized	intramuscularly	in	both	hind	leg	muscles	(quadriceps)	with	
escalating	doses	(107,	108,	109	or	1010	viral	particles	(vp))	of	Ad5	or	Ad26	vectors	per	mouse.	
Mice	were	boosted	60	days	post	prime	intramuscularly	with	MVA	at	a	dose	of	≤107	plaque-
forming	units	(PFU)	or	Ad35-SIVmac239	Gag	(109	vp).	Intramuscular	(i.m)	injections	were	
administered	in	100	μl	phosphate-buffered	saline	(PBS)	solution	(50	μl	per	quadricep).	Animals	
were	housed	at	the	Beth	Israel	Deaconess	Medical	Centre	(BIDMC)	animal	facility	and	all	
experiments	were	performed	according	to	approved	IACUC	protocol.		
	
2.2.2 Isolation	of	lymphocytes	
Single-cell	suspensions	of	blood	and	tissues	were	generated	as	previously	described71,	
111.	Briefly,	mouse	blood	was	collected	in	RPMI	1640	containing	40U/ml	heparin.	PBMCs	were	
isolated	from	whole	blood	using	Ficoll-Hypaque	density	centrifugation	at	1900	rpm	for	20	min.	
Liver,	lymph	node	and	spleen	were	homogenized	to	single	cell	suspension	by	forcing	tissue	
chunk	through	a	100µm	sterile	cell	strainer	using	the	barrel	of	a	5-cc	syringe.	Red	blood	cells	
were	lysed	using	ammonium	chloride	(ACK)	Lysing	Buffer	(ThermoFischer).	Resulting	cell	
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suspension	was	pelleted,	re-suspended	in	RPMI	containing	10%	fetal	calf	serum	and	
penicillin/streptomycin.	Cells	were	counted	thereafter.	Homogenized	liver	tissue	was	applied	to	
a	44/67%	Percoll	gradient	and	centrifuged	at	2,000	rpm	for	10	min	at	20oC.	The	interface	
containing	the	intrahepatic	lymphocyte	population	was	harvested	and	washed,	and	the	
resulting	lymphocytes	suspension	was	re-suspended	in	RPMI	containing	10%	fetal	calf	serum	
and	penicillin/streptomycin,	and	counted.		
	
2.2.3 Tetramer	binding	assay	and	flow	cytometry	
MHC	class	I	tetramer	staining	was	performed	on	single	cell	suspension	using	an	H-2Db	
tetramer	folded	around	the	immunodominant	SIV	Gag	AL11	epitope	(AAVKNWMTQTL)	as	
described	previously112.	Biotinylated	class	I	monomers	were	obtained	from	the	National	
Institutes	of	Health	Tetramer	Core	Facility	(Emory	University,	GA)	and	tetramerised	in-house.	
Background	staining	of	CD8	T	cells	from	naïve	animals	was	≤	0.1%.	Surface	staining	was	
performed	with	anti-CD8a	(53-	6.7),	-CD44	(IM7),	-CD127	(A7R34),	-CD62L	(MEL-14),	-KLRG1	
(2F1)	and	-PD-1	(RMP1-30).	Transcription	factor	staining	was	performed	by	first	permeabilizing	
the	cells	with	the	FoxP3	Fixation/Permeabilization	Kit	(eBioscience)	and	subsequently	staining	
with	anti-T-bet	(4B10),	–Eomes	(Dan11mag)	and	–FoxP3	(150D/E4).	All	Antibodies	were	
purchased	from	BD	Biosciences,	eBioscience,	or	BioLegend.	Live/Dead	Fixable	Near-IR	staining	
kit	was	obtained	from	Life	Technologies.	After	staining,	cells	were	washed	in	PBS	containing	2%	
fetal	bovine	serum	(FBS)	and	fixed	using	cytofix/cytoperm	buffer	(BD	Bioscience).	Samples	were	
acquired	on	an	LSR	II	flow	cytometer	(BD	Biosciences),	and	data	were	analyzed	using	FlowJo	
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version	9.7.7	(Tree	Star).	
2.2.4 Intracellular	cytokine	staining	(ICS)	assays	
Cytokine	expression	of	Gag-specific	cellular	immune	responses	in	immunized	mice	was	
assessed	by	multiparameter	intracellular	cytokine	staining	(ICS)	assays	as	previously	
described110,	with	some	modifications.	Briefly,	lymphocytes	isolated	from	the	blood	(~5x105),	
spleen	(106)	or	the	liver	(106)	were	incubated	for	5	hours	at	37	°C	with	0.2	μg/ml	of	SIV	Gag	
peptide	pool	(together	with	brefeldin	A	(GolgiPlug)	and	monensin	(GolgiStop).	After	incubation,	
cells	were	stained	with	anti-CD8	(53-6.7),	-CD44	Pacific	Blue	(IM7),	-CD4	(RM4-5)	and	Live/Dead	
Fixable	Near-IR	staining	kit.	Afterwards,	cells	were	fixed	and	permeabilized	with	
Cytofix/Cytoperm	prior	to	intracellular	staining	with	anti-IFN-γ	(XMG1.2),	anti-TNF	(MP6-XT22),	
and	anti-IL-2	(JES6-5H4).	All	ICS	reagents	were	purchased	from	BD	Biosciences.		
	
2.2.5 Monoclonal	antibodies	treatments	
PD-L1	blockade	was	achieved	via	injection	of	200	microgram	10F.9G2	(BioXCell)	at	the	
time	of	priming	or	boosting	immunization.	The	regimen	consisted	of	five	doses	every	3	days	as	
previously	described100,	with	the	first	dose	given	a	day	prior	to	immmunization.	All	antibodies	
(ab)	were	diluted	in	DPBS	and	administered	intraperitoneally	(i.p).	Rat	IgG2b	(BioXCell)	was	
used	as	control.	Memory	CD8	T	cell	recall	responses	were	assessed	in	blood	on	day	7,	and	in	
blood	and	tissues	on	day	15	post	boost.	
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2.2.6 In	vitro	Treg	suppression	assay	
In	vitro	Treg	suppression	assay	was	performed	as	previously	described113,	with	some	
modifications.		Briefly,	CD4	T	cells	were	enriched	by	negative	magnetic	selection	from	the	
spleen	of	adenoviral	vector-immunized	Foxp3gfp	mice	(pooled	from	2	spleens	per	group)	using	
an	EasySep™	Mouse	CD4	T	Cell	Isolation	Kit	(Stemcell	Technologies).	After	enrichment	of	CD4	T	
cells,	FoxP3+GFP+	CD4	T	cells	were	sorted	using	a	FACSAria	II	cell	sorter	(BD	Bioscience).	Naive	
CD8	T	cells	were	isolated	from	the	spleen	of	C57BL/6	mice,	labeled	with	Cell	Trace	Violet	(CTV)	
dye	(5	μM;	Life	Technologies)	for	10	min	at	room	temperature	in	PBS	and	washed	with	
complete	media	before	culture.	For	the	suppression	assay,	2.5	x	104	CTV-labelled	CD8	T	cells	
were	co-cultured	with	Dynabeads®	Mouse	T-Activator	CD3/CD28	beads	(ThermoFischer	
Scientific)	at	a	ratio	of	4	to	5	(beads:CD8	T	cells),	and	varying	numbers	(0,	1.5x	103,	3x103,	6x103,	
1.25x104,	2.5x104)	of	sorted	FoxP3+GFP+	CD4	T	cells	per	well	in	a	96-well	flat	bottom	plate.	After	
72	h	of	incubation	at	37oC,	cells	were	harvested,	stained	with	anti-CD8a	(53-6.7),	-CD44	(IM7),	
and	-CD4	(RM4-5),	-CD25	(3C7)	and	Live/Dead	Fixable	Near-IR	staining	kit	(RMP1-30).	CD8	T	
cells	were	analyzed	for	CTV	dilution	by	flow	cytometry.	
	
2.2.7 Statistical	analysis	
Statistical	analysis	was	performed	on	GraphPad	Prism	version	6.0h	using	two-tailed	
nonparametric	Mann-Whitney	U	test.		
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2.3 Results	
2.3.1 The	kinetics,	phenotype	and	functionality	of	vaccine-induced	CD8	T	cells	following	
vaccination	with	different	doses	of	Ad5	
We	initiated	studies	by	assessing	the	magnitude,	phenotype	and	quality	of	transgene-
specific	CD8	T	cells	elicited	by	different	doses	of	Ad5	vector.	We	immunized	6-8	week	old	
C57BL/6	mice	intramuscularly	(i.m)	with	escalating	doses	of	Ad5	(108,	109	and	1010	vp)	
expressing	the	Gag	antigen	from	SIV	strain	mac239.	Gag-specific	CD8	T	cell	responses	in	
peripheral	blood	were	assessed	longitudinally	using	an	MHC	class	I	tetramer	loaded	with	the	
immunodominant	epitope	AL11112.	Mice	vaccinated	with	1010	vp	of	Ad26	expressing	the	same	
antigen	also	were	included	as	control	(Fig.	1A).	Consistent	with	previous	reports78,	81,	all	doses	
of	Ad5	elicited	similar	peak	CD8	T	cell	responses	at	day	15	post-prime,	but	the	low	dose	Ad5	
prime	(108	vp)	was	associated	with	more	pronounced	CD8	T	cell	contraction	compared	to	high	
dose	Ad5	prime	(1010)	(p<0.001)	(Fig.	1B-1C).	
Next,	we	examined	the	phenotype	of	Db-AL11+	CD8	T	cells	following	vaccination	with	
different	doses	of	Ad5.	It	has	previously	been	shown	that	Ad5,	compared	to	alternate	serotype	
Ad	vectors	such	as	Ad26	and	Ad35,	leads	to	an	up-regulation	of	the	immunoinhibitory	receptor,	
PD-1	on	vaccine-elicited	CD8	T	cells23,	81.	We	therefore	sought	to	assess	whether	PD-1	up-
regulation	on	Ad5-elicited	CD8	T	cells	is	dose-dependent.	We	noticed	that	antigen-specific	CD8	
T	cells	in	mice	primed	with	low	dose	Ad5	expressed	significantly	lower	PD-1	relative	to	high	
dose	Ad5-primed	mice	at	the	peak	of	the	primary	response	(day	15	post	immunization	(p.i))	
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(p<0.0001;	Fig.	2A)	and	at	memory	time-point	(day	60	p.i)	(p=0.0059;	Fig.	2B),	suggesting	that	
PD-1	expression	on	Ad5-elicited	CD8	T	cells	is	dose-dependent.	
We	further	assessed	the	cell	surface	expression	of	killer	cell	lectin-like	receptor	G1	
(KLRG1)	and	IL-7	receptor	alpha-chain	(CD127),	two	markers	often	used	to	delineate	terminal	
(KLRG1+	CD127-)	and	memory	precursor	(KLRG1-CD127+)	effector	CD8	T	cells	in	mice114,	115.	We	
found	that,	on	day	60	post	immunization,	the	proportion	of	KLRG1+CD127–	memory	precursor	
effector	cells	(MPECs)	in	blood	was	reduced	in	the	low	dose	Ad5-immunized	group	compared	
with	the	high	dose	group	(Ad5	108	vp,	18%	MPECs;Ad5	1010	vp,	10%	MPECs;	p<0.05),	while	
there	was	a	corresponding	higher	proportion	of	KLRG1+CD127–	short	lived	effector	cells	(SLECs)	
in	mice	immunized	with	high	dose	Ad5	relative	to	low	dose	Ad5-immunized	mice	(Ad5	108	vp,	
45%	MPECs	;Ad5	1010	vp,	50%	MPECs;	p<0.05)	(Fig.	2C).	This	suggests	that	there	is	a	
preferential	differentiation	of	vaccine-induced	effector	CD8	T	cells	towards	the	memory	
precursor	lineage	following	low	dose	Ad5	immunization	compared	with	high	dose	Ad5	
immunization.			
Polyfunctional	T	cells	are	T	cells	which	secrete	multiple	cytokines	concurrently.	They	
have	been	shown	to	play	an	essential	role	in	the	control	of	HIV	infection,	and	correlate	with	
protection	in	some	vaccine	models2,	116,	117,	118.	Therefore,	we	assessed	the	ability	of	vaccine-
elicited	memory	CD8	T	cells	to	secrete	multiple	cytokines	following	ex-vivo	antigen	re-
stimulation	with	an	overlapping	SIV	Gag	peptide	pool.	We	observed	that	low	dose	Ad5	induces	
a	higher	frequency	of	Gag-specific	CD8	T	cells	co-expressing	two	(IFN-γ	and	TNF-α)	or	three	
(IFN-γ,	TNF-α	and	IL-2)	cytokines,	while	high	dose	Ad5	leads	to	the	induction	of	more	CD8	T	
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cells	expressing	only	IFN-γ	relative	to	low	dose	Ad5	(P=0.0029	(for	Ad5	108	vp	versus	Ad5	1010	
vp;	IFN-γ,	TNF-α	and	IL-2	co-producers);	P<0.0001	(for	Ad5	108	vp	versus	Ad5	1010	vp;	IFN-γ	and	
TNF-α	co-producers);	P<0.0001	(for	Ad5	108	vp	versus	Ad5	1010	vp;	IFN-γ	only)	(Fig.	2D).	For	all	
parameters	examined,	the	phenotype	and	quality	of	CD8	T	cells	induced	by	low	dose	Ad5	
closely	resembles	those	of	Ad26-induced	CD8	T	cells	(Fig.	1B-1C;	Fig.	2A-2D).	Altogether,	these	
findings	build	on	previous	reports	by	showing	that	low	dose	Ad5	vector	is	as	similarly	
immunogenic	as	high	dose	Ad5	and	yet	elicits	a	more	functional	transgene-specific	CD8	T	cell	
population	characterized	by	lower	PD-1	expression,	enhanced	memory	conversion	and	
improved	functionality.	
	
2.3.2 Improved	anamnestic	CD8	T	cell	responses	after	vaccination	with	low	dose	Ad5	vector	
It	has	previously	been	shown	that,	compared	with	alternative	adenovirus	serotype,	Ad5-
induced	CD8	T	cells	exhibit	reduced	anamnestic	expansion	following	a	heterologous	vector	
boost23,	81	or	a	secondary	antigen	challenge119.	We	therefore	sought	to	assess	the	recall	
expansion	of	the	phenotypically	favorable	CD8	T	cell	induced	by	low	dose	Ad5	compared	with	
CD8	T	cells	induced	by	high	dose	Ad5.	Mice	vaccinated	with	escalating	doses	of	Ad5	or	a	fixed	
dose	of	Ad26	vectors	expressing	SIV	Gag	were	boosted	with	Ad35	vector	expressing	the	same	
SIV	Gag	transgene	(Fig.	2A).	Intriguingly,	we	observed	a	robust	recall	expansion	of	low-dose	Ad5	
primed	CD8	T	cells	compared	with	high	dose	Ad5	prime	by	day	7	post-boost	(difference	
between	pre	and	post-boost	for	low	dose	Ad5	was	5.37-fold;	for	high	dose	Ad5,	1.92-fold;	a	2.8-
fold	difference,	p=0.0012)	(Fig.	3B-3D).	Similarly,	on	day	14	and	30	post	boost,	there	was	a	
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trend	towards	a	higher	number	of	Gag-specific	CD8	T	cells	in	the	group	primed	with	low	dose	
Ad5	compared	with	high	dose	Ad5-primed	mice,	although	this	was	not	significant	(data	not	
shown)		
On	day	7	post	boost,	we	analyzed	the	phenotype	of	antigen-specific	CD8	T	cells	in	blood.	
We	observed	a	higher	expression	of	Ki-67,	a	marker	of	proliferative	potential,	on	Gag-specific	
CD8	T	cells	from	low	dose	Ad5-primed	mice	compared	with	high	dose	Ad5-primed	(Fig.	2E)	(p=	
0.029),	correlating	with	the	improved	recall	expansion	seen	in	the	low	dose	group.	Additionally,	
granzyme	B	expression	on	Gag-specific	CD8	T	cells	in	low	dose	Ad5-vaccinated	mice	was	greater	
than	those	of	high	dose	Ad5-vaccinated	mice	following	boost,	suggesting	improved	cytotoxic	
potential	(Fig.	2F)	(p=	0.029).	Furthermore,	antigen-specific	CD8	T	cells	in	mice	primed	with	low	
dose	Ad5	expressed	significantly	lower	PD-1	relative	to	high	dose	Ad5-primed	mice	following	
boost	(Fig.	3G)	(p<	0.0005).	No	significant	differences	were	observed	among	dose	groups	in	the	
expression	of	other	phenotypic	markers	such	as	CD127,	KLRG-1	or	the	lymphoid	homing	
receptor	CD62L	(data	not	shown).	
		 To	determine	the	functionality	of	vaccine-elicited	CD8	T	cells	following	heterologous	
boost,	we	isolated	splenocytes	on	day	30	post	boost	and	analyzed	their	ability	to	express		IFN-γ,	
TNF-α	and	IL-2	concurrently	after	re-stimulation	with	Gag	peptide.	We	showed	that	the	number	
of	individual	vaccine	elicited	CD8	T	cells	co-expressing	three	cytokines	was	significantly	greater	
in	low	dose	Ad5-primed	mice	compared	with	high	dose	Ad5-primed	mice	(Fig.	4A-4C).	In	line	
with	this	finding,	we	also	observed	that	the	frequency	of	Gag-specific	CD8	T	cells	co-producing	
IFN-γ	and	TNF-α		in	mice	primed	with	low	dose	Ad5	was	2.4%	compared	with	0.8%	in	low	dose	
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Ad5-primed	mice,	a	3	fold	difference	(P	=	0.031),	while	the	frequency	of	Gag-specific	CD8	T	cells	
co-producing	IFN-γ	and	IL-2	was	4	fold	higher	in	low	dose	Ad5-primed	mice	than	in	high	dose	
Ad5	primed	mice	(%	of	CD8	T	cells	co-producing	IFN-γ	and	IL-2:	mean	(low	dose	Ad5)	=	0.3%,	
mean	(low	dose	Ad5)	=	0.07%;	P	=	0.0079).	Representative	flow	cytometry	plots	of	cytokine	co-
expression	on	Gag-specific	CD8	T	cells	are	shown	(Fig.	4D).	Furthermore,	we	found	that	the	
proportion	of	cells	co-expressing	all	three	cytokines	(IFN-γ,	TNF-α	and	IL-2)	was	significantly	
higher	in	the	low	dose	group	compared	with	the	high	dose	(P=0.008)	(Fig.	4E).	However,	there	
was	no	difference	in	the	per	cell	expression	of	these	cytokines	(data	not	shown).	Similar	
findings	were	seen	following	an	MVA	boost	(data	not	shown).	Taken	together,	these	data	
suggest	that	lowering	the	dose	of	Ad5	at	prime	will	improve	anamnestic	recall	of	vaccine-
induced	memory	CD8	T	cells,	their	cytotoxic	potential,	and	functionality,	without	compromising	
the	magnitude	of	its	primary	response.		
	 	
2.3.3 Excessive	up-regulation	of	PD-1	on	Ad5-induced	memory	CD8	T	cells	impairs	their	
recall	response	
Higher	PD-1	expression	on	memory	CD8	T	cells	has	previously	been	shown	to	correlate	
with	impaired	memory	recall	in	some	models	of	immune	exhaustion102.	We	therefore	reasoned	
that	the	higher	PD-1	expression	on	high	dose	Ad5-induced	memory	CD8	T	cells	may	be	
responsible	for	the	blunting	of	recall	response.	Data	from	pre-clinical	and	clinical	studies	have	
shown	that	PD-1	blockade	can	be	achieved	by	in	vivo	administration	of	either	anti–PD-1	or	anti–
PD-1	ligand	(aPD-L1)100,	120,	121,	122,	123,	124.	To	assess	the	functional	significance	of	PD-1	expression	
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on	Ad5	induced	memory	CD8	T	cells,	we	inhibited	the	PD-L1:PD-1	pathway	by	administering	
anti-PD-L1	blocking	antibody	(aPD-L1)	at	the	time	of	boosting	with	a	heterologous	vector,	Ad35	
(Fig.	5A).	Mice	vaccinated	with	Ad26	were	used	as	control	since	CD8	T	cells	elicited	by	this	
vector	are	not	associated	with	high	PD-1	expression23.	Treatment	with	anti-PD-L1	significantly	
enhanced	the	recall	response	of	Ad5-induced	memory	CD8	T	cells	following	boost,	as	compared	
with	controls	(3.8	fold	expansion	in	PD-L1	blockade	group,	compared	with	1.6	fold	expansion	in	
isotype	control	group,	P=0.0317)	(Fig.	5B-5C).		Similar	treatment	of	Ad26-induced	memory	CD8	
T	cells	does	not	alter	memory	recall.	This	suggests	that	the	improvement	in	recall	response	
observed	following	anti-PD-L1	treatment	can	only	occur	in	the	context	of	high	PD-1	expression.	
We	also	did	not	observe	any	differential	up-regulation	of	PD-L1	expression	on	T	cells	or	DCs	
following	Ad5	vaccination	compared	to	Ad26	immunization	(data	not	shown),	suggesting	that	
the	effect	is	a	CD8	T	cell	intrinsic	phenomenon.	There	were	no	differences	in	expression	profiles	
of	phenotypic	markers	such	as	CD62L,	CD127,	or	KLRG-1	on	the	expanded	Gag-specific	memory	
CD8	T	between	both	treatment	groups	(data	not	shown)	.	On	day	14	post	boost,	we	isolated	
splenocytes	and	assessed	the	functionality	of	Gag	specific	CD8	T	cells	as	described	earlier.	In	the	
Ad5-immunized	group,	we	found	a	higher	frequency	of	IFN-γ-producing	Gag-specific	CD8	T	cells	
(P=0.04)		and	TNF-α	producing	Gag-specific	CD8	T	cells	(P	=0.03)	following	anti-PD-L1-treatment	
compared	to	untreated	(Fig.	5D	and	5E).	There	was	no	significant	difference	in	frequency	of	IL-
2-producing	Gag-specific	CD8	T	cells	between	both	groups	(Fig.	5F).	However,	there	was	a	trend	
towards	a	more	polyfunctional	antigen-specific	CD8	T	cells	in	the	treatment	group	compared	
with	those	untreated	(Fig.	5G).			
		
29	
To	determine	the	effect	of	blocking	PD-1	signaling	pathway	on	the	primary	immune	
responses	of	Ad5	vector	and	assess	if	this	early	blockade	will	lead	to	a	similar	improvement	in	
memory	recall	as	seen	when	the	PD-1	pathway	was	blocked	at	a	later	time-point,	we	
administered	anti-PD-L1	treatment	at	the	time	of	Ad5	prime	(Fig.	6A).	Mice	were	followed	
longitudinally	to	assess	tetramer	kinetics	in	blood,	and	boosted	with	Ad35	on	day	60	post	
immunization	to	assess	memory	recall.	We	observed	that	PD-1	blockade	does	not	alter	the	
kinetics	of	primary	response	in	both	Ad5-	or	Ad26-primed	mice.	In	addition,	there	was	no	
difference	in	expression	level	of	surface	markers	like	CD62L,	CD127	and	KLRG-1	(data	not	
shown),	and	cytokine	co-expression	on	gag-specific	CD8	T	cells	was	similar	in	both	treated	and	
control	group	(Fig.	6C).	In	addition,	PD-L1	blockade	at	prime	does	not	lead	to	a	significant	
enhancement	of	memory	recall	following	a	heterologous	Ad35	boost	(Fig.	6E	and	6F).	Taken	
together,	these	data	suggest	that	the	establishment	of	an	“immune	dysfunction”	state	
characterized	by	up-regulation	of	PD-1	is	required	for	PD-1	blockade	to	have	a	significant	effect	
on	recall	response	
	
2.3.4 Similar	Tregs	frequency	and	suppressive	function	in	Ad5-	and	Ad26-immunized	mice		
Regulatory	T	cells	have	been	shown	to	modulate	CD8	T	cell	activation,	proliferation,	
differentiation	and	memory	recall125.	Increased	frequency	and	suppressive	function	of	FoxP3+	
CD4	T	cells	have	been	reported	in	LCMV	clone	13	infection,	a	mouse	model	of	chronic	infection,	
in	which	PD-1	is	up-regulated107,	126.	As	a	prelude	to	determining	whether	Tregs	may	play	a	role	
in	the	impaired	memory	recall	associated	with	Ad5-elicited	CD8	T	cells,	we	sought	to	determine	
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whether	Tregs	following	Ad5	immunization	are	differentially	activated	compared	to	alternative	
serotype	Ad	vector	immunized	mice.	We	vaccinated	FoxP3gfp	mice	with	Ad5	expressing	SIV	Gag	
or	Ad26	expressing	SIV	Gag	and	assessed	the	frequency	of	FoxP3+	CD4	T	cells	at	the	peak	of	
infection	(day	15	p.i)	(Fig.	7A).	Tregs	isolated	from	naïve	mice	or	LCMV	clone	13	infected	mice	
served	as	controls.	As	expected,	the	frequency	of	Tregs	was	significantly	higher	in	LCMV	clone	
13	infected	mice	compared	to	naïve	or	Ad-immunized	mice.	However,	the	number	and	
frequency	of	FoxP3+	CD4	T	cells	in	the	spleen	and	blood	of	Ad5	immunized,	Ad26	immunized	
and	naïve	mice	was	similar.	Representative	flow	cytometry	plots	are	shown	in	Fig.	7A.	To	assess	
whether	there	is	a	difference	in	the	suppressive	capacity	of	Tregs	induced	by	these	vectors,	we	
isolated	splenocytes	from	Ad5	or	Ad26	vaccinated	mice,	enriched	for	CD4	T	cells	followed	by	
FACS	sorting	for	GFP+	Tregs.	We	co-culture	isolated	Tregs	with	Cell	Trace	Violet	(CTV)-labeled	
naive	CD8	T	cells	(target	cells)	isolated	from	naïve	mice,	in	the	presence	of	antiCD3/antiCD28	
beads,	and	assessed	CD8	T	cell	proliferation	72	hours	following	incubation.	Interestingly,	we	
observed	that	at	peak	primary	response	(day	15	post	immunization),	Tregs	from	Ad5	
immunized	and	Ad26	immunized	mice	were	similarly	suppressive	of	CD8	proliferation,	with	
both	being	less	suppressive	compared	with	naïve,	and	Tregs	from	Clone	13	infected	mice	being	
the	most	suppressive	amongst	all	groups	(Fig.	7B-7C).	Although	more	rigorous	investigations	
are	required,	these	results	suggest	that	regulatory	T	cells	may	not	play	an	important	role	in	the	
impaired	immune	recall	seen	with	Ad5,	further	supporting	the	hypothesis	that	the	impaired	
immune	response	seen	following	Ad5	immunization	is	probably	a	CD8	T	cell	intrinsic	
phenomenon.		
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2.4 Figures		
2.4.1 Figure	1:	Kinetics	of	vaccine-elicited	CD8	T	cell	following	vaccination	with	different	
doses	of	Ad5	
(A)	Experimental	outline.	(B)	Representative	flow	cytometry	plots	showing	the	percentages	of	
Gag-specific	CD8	T	cells	in	blood	following	immunization	with	Ad5-SIVGag	(108,	109,	and	1010)	vp	
or	Ad26-SIVGag	(1010	vp)	(C)	Number	of	Gag-specific	CD8	T	cells	in	blood.	Data	are	representative	
of	at	least	three	independent	experiments,	with	n=4-5	mice	per	group	per	experiment.	Error	bars	
represent	standard	errors	of	the	means	(SEM).;	***,	P	<	0.001;	ns;	not	significant.	
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2.4.2 Figure	2:	Phenotype	and	polyfunctionality	of	vaccine-induced	CD8	T	cell	
following	vaccination	with	different	doses	of	Ad5.		
	 															 		
			 			
	
(A	and	B)	MFI	of	PD-1	on	Gag-specific	CD8	T	cells	in	blood	at	(A)	peak	time	point	(Day	15	p.i)	and	at	
(B)	memory	time	point	(Day	60p.i)	following	immunization	with	indicated	doses	of	Ad5	and	Ad26.	(C)	
Proportion	(%)	of	Gag-specific	CD8	T	cells	that	express	various	combinations	of	CD127/KLRG1	at	day	
60	following	Ad5	or	Ad26	vaccination.	(D)	Proportion	(%)	of	total	Gag-specific	CD8	T	cells	in	blood	co-
expressing	3	(IFN-γ,	TNF-α	and	IL-2)	cytokines,	2	(IFN-γ	and	TNF-α)	cytokines	or	1	(IFN-γ)	cytokine	at	
day	60	 following	Ad5	or	Ad26	 vaccination.	Data	 are	 representative	of	 at	 least	 three	 independent	
experiments,	with	n=4-5	mice	per	group	per	experiment.	Error	bars	represent	standard	errors	of	the	
means	(SEM).	*,	P	<	0.05;	**,	P	<	0.01;	***,	P	<	0.001;	****,	P	<	0.001		
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2.4.3 Figure	3:	Lowering	the	priming	dose	of	Ad5	vector	partially	improves	the	
phenotype	and	the	recall	responses	after	Ad35	boosting.		
	
(A)	Experimental	outline.	(B)	Representative	FACS	plots	showing	the	percentages	of	Gag-specific	CD8	
T	cells	in	blood	pre	and	post	Ad35	boost.	(C)	Number	of	Gag-specific	CD8	T	cells	in	blood.	(D)	Summary	
showing	the	fold-increase	of	Gag-specific	CD8	T	cells	in	blood	after	Ad35	boost.	(E)	MFI	of	Ki-67	on	
Gag-specific	CD8	T	cells	in	blood	on	Day	7	post	Ad35	Boost.	(F)	MFI	of	Granzyme	B	on	Gag-specific	
CD8	T	cells	in	blood	on	Day	7	post	Ad35	Boost.	(G)	MFI	of	PD-1	on	Gag-specific	CD8	T	cells	in	blood	
on	Day	7	post	boost.	Data	are	representative	of	two	independent	experiments,	with	n=4-5	mice	per	
group	per	experiment.	Error	bars	represent	standard	errors	of	the	means	(SEM).	*,	P	<	0.05;	**,	P	<	
0.01;	ns,	not	significant;	vp,	viral	particle.	
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2.4.4 Figure	4:	Priming	with	low	dose	Ad5	in	a	Ad5-Ad35	heterologous	prime-boost	
regimen	produce	more	polyfunctional	CD8	T	cells.		
	 		
	 		
(A-C)	Number	of	splenic	Gag-specific	CD8	T	cells	expressing	(A)	IFN-γ,	(B)	TNF-α,	and	(C)	IL-2	on	
day	30	 following	Ad35	boost	 (D)	 Representative	FACS	plots	 showing	 the	percentages	of	Gag-
specific	CD8	T	cells	 in	spleen	co-expressing	 IFN-γ	and	TNF-α,	or	 IFN-γ	and	 IL-2	 following	Ad35	
boost.	(E)	Proportion	(%)	of	total	Gag-specific	CD8	T	cells	in	spleen	co-expressing	3	(IFN-γ,	TNF-α	
and	IL-2)	cytokines,	2	(IFN-γ	and	TNF-α)	cytokines	or	1	(IFN-γ)	cytokine	at	day	30	following	Ad35	
boost.	Data	are	representative	of	two	independent	experiments,	with	n=4-5	mice	per	group	per	
experiment.	Error	bars	represent	standard	errors	of	the	means	(SEM).	*,	P	<	0.05;	**,	P	<	0.01;	
ns,	not	significant;	vp,	viral	particle.	
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2.4.5 Figure	5:	Excessive	up-regulation	of	PD-1	on	Ad5-induced	memory	CD8	T	cells	
impairs	their	recall	response.		
(A)	Experimental	outline.	(B)	Number	of	Gag-specific	CD8	T	cells	in	blood	following	Ad35	boost	
+/-	aPD-L1	or	IgG	treatment.	(C)	Summary	showing	the	fold-increase	of	Gag-specific	CD8	T	cells	
in	blood	after	Ad35	boost	+/-	aPD-L1	or	IgG	treatment.	(D-F)	Percentage	of	splenic	Gag-specific	
CD8	T	cells	expressing	(D)	IFN-γ,	(E)	TNF-α,	and	(F)	IL-2	on	day	14	following	Ad35	boost	+/-	aPD-
L1	or	IgG	treatment.	(G)	Proportion	(%)	of	total	Gag-specific	CD8	T	cells	in	spleen	co-expressing	3	
(IFN-γ,	TNF-α	and	IL-2)	cytokines,	2	(IFN-γ	and	TNF-α)	cytokines	or	1	(IFN-γ)	cytokine	at	day	30	
following	 Ad35	 boost	 in	 Ad5-primed	 mice.	 Data	 are	 representative	 of	 two	 independent	
experiments,	with	n=4-5	mice	per	group	per	experiment.	Error	bars	represent	standard	errors	of	
the	means	(SEM).	*,	P	<	0.05;	**,	P	<	0.01;	ns,	not	significant;	vp,	viral	particle.	
		
36	
2.4.6 Figure	6:	PD-L1	blockade	prior	to	priming	does	not	affect	the	kinetics,	memory	
conversion	or	anamnestic	response	of	Ad5-induced	CD8	T	cells	
	
	
	
	
	
	
		
	
(A)	Experimental	outline.	(B)	Number	of	Gag-specific	CD8	T	cells	in	blood	following	Ad5	or	Ad26	
immunization	 +/-	 aPD-L1	 or	 IgG	 treatment.	 (C)	 Representative	 FACS	 plots	 showing	 the	
percentages	of	Gag-specific	CD8	T	cells	 in	spleen	(D60	post	 immunization)	co-expressing	IFN-γ	
and	 TNF-α,	 or	 IFN-γ	 and	 IL-2	 following	 Ad5	 or	 Ad26	 immunization	 +/-	 aPD-L1	 or	 control	 IgG	
treatment.	(D)	Number	of	Gag-specific	CD8	T	cells	in	blood	following	Ad35	boost	(E)	Summary	
showing	 the	 fold-increase	 of	 Gag-specific	 CD8	 T	 cells	 in	 blood	 after	 Ad35	 boost.	 Data	 are	
representative	 of	 two	 independent	 experiments,	with	 n=4-5	mice	 per	 group	per	 experiment.	
Error	bars	represent	standard	errors	of	the	means	(SEM).	ns,	not	significant;	vp,	viral	particle.	
TNF-	! IL-2 
IF
N-
γ 
		
37	
2.4.7 Figure	7:	Similar	Treg	frequencies	and	suppressive	functions	in	Ad5-	and	Ad26-	
immunized	mice.		
	(A)	Experimental	outline.	(B)	Representative	FACS	plots	showing	the	percentages	of	foxP3+	CD4	
T	cells	in	spleen	on	day	15	following	vaccination	with	Ad5	1010vp	and	Ad26	1010vp.	Control	are	
naïve	mice	and	LCMV	clone	13	infected	mice.	(C)	Suppression	of	CD8	T	cell	proliferation	by	Tregs	
isolated	at	day	15	following	vaccination	with	Ad5	1010vp	and	Ad26	1010vp.	Numbers	represent	
percentage	of	proliferating	cells.	(D)	Summary	showing	percentage	proliferation	of	CD8	T	cells	at	
day	15	following	vaccination	with	Ad5	1010vp	and	Ad26	1010vp	Data	are	representative	of	two	
independent	experiments,	with	n=4-5	mice	per	group.	Suppression	assay	was	done	in	triplicates.	
Error	bars	represent	standard	errors	of	the	means	(SEM).;	**,	P	<	0.01;	ns,	not	significant;	vp,	
viral	particle.	
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3. Chapter	3:	Discussion	and	perspectives	
The	induction	of	high	magnitude	CD8	T	cell	responses	has	been	shown	to	correlate	with	
vaccine-mediated	protection	against	ebola,	malaria	and	SIV3,	4,	127.	Although	a	single	
administration	of	an	Ad	vector	can	elicit	detectable	CD8	T	cell	responses,	heterologous	prime-
boost	regimens	are	typical	used	to	generate	higher	magnitude	responses	in	conventional	
vaccination	regimes.	As	a	stand	alone	vaccine,	Ad5	elicits	high	magnitude	CD8	T	cell	response	
that	confer	some	protection	in	preclinical	studies78.	However,	following	a	heterologous	boost,	
these	primary	CD8	T	cells	exhibit	an	impaired	proliferative	capacity,	which	subsequently	
impacts	protective	efficacy23.	Further	evaluation	has	revealed	that	the	primary	CD8	T	cells	
induced	by	Ad5	vaccination	display	a	partially	exhausted	phenotypic	profile	characterized	by	
high	expression	of	immunoinhibitory	receptors,	poor	polyfunctionality,	and	an	impaired	
memory	conversion,	comparable	with	chronic	LCMV	infection	in	mice23,	83.		In	this	study,	we	
evaluated	the	mechanism	underlying	Ad5-induced	impaired	immune	responses	by	assessing	
the	effect	of	reducing	vector	dose,	blocking	PD-1	signaling	pathway,	and	evaluating	treg–
mediated	suppression	following	Ad5	immunization.	
First,	we	corroborated	earlier	findings	that	the	reduction	of	vector	dose	significantly	
improves	the	phenotypic	and	qualitative	profiles	of	transgene-specific	CD8	T	cells	without	
affecting	the	magnitude	of	the	primary	immune	response.	We	then	extended	this	observation	
by	showing	that	vector	dose	reduction	and	PD-1	signaling	blockade	result	in	an	improvement	in	
Ad5-induced	immune	dysfunction	as	evidenced	by	the	improved	memory	recall	following	
boost.	Finally,	we	showed	that,	compared	to	alternative	serotype	adenovirus,	Ad5	
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immunization	does	not	differentially	affect	the	magnitude	or	suppressive	function	of	Tregs.	
Taken	together,	these	data	provide	some	mechanistic	understanding	of	Ad5-induced	immune	
dysfunction.		
In	broad	terms,	the	factors	influencing	immune	response	elicited	by	Ad	vectors	may	be	
categorized	into	virological	and	immunological	factors	(Figure	A).	Possible	virological	factors	
include	the	serotype	of	the	Ad	vector,	its	cellular	receptor	specificity,	intracellular	trafficking	
route	employed	by	the	vector,	the	vector	dose	or	route	of	administration.	In	terms	of	
immunological	factors	influencing	Ad5-induced	immune	dysfunction,	these	may	either	be	CD8	T	
cell	intrinsic	or	CD8	T	cell	extrinsic.	Likely	intrinsic	factors	are	immunoinhibitory	receptors		
expressed	on	CD8	T	cells,	transcription	factors	(e.g.	T-bet	and	Eomes)	or	epigenetic	factors,	
such	as		DNA	expression	regulatory	enzymes	(e.g.	histone	deacetylases	(HDAC)),	similar	to	what	
has	been	observed	in	chronic	LCMV	infection128,	129.	Extrinsic	CD8	T	cell	factors	include	the	
innate	immune	system,	such	as	innate	cytokine	and	chemokine	profiles	or	the	subset	of	
dendritic	cells	transduced.	Other	extrinsic	factors	include	the	induction	of	co-stimulatory	or	co-
inhibitory	molecules	e.g.	PD-L1	on	transduced	antigen	presenting	cells,	or	the	effect	of	other	
cells	of	the	adaptive	immune	system	such	as	conventional	CD4	T	cells	or	regulatory	T	cells.	All	
these	factors	are	known	to	play	important	roles	in	the	development	and	maintenance	of	T	cell	
exhaustion	in	classical	models	of	immune	exhaustion.	
It	is	known	that	the	dose	and	duration	of	antigenic	stimulation	profoundly	affect	the	
phenotype,	differentiation,	functionality,	and	proliferative	capacity	of	effector	T	cells	
produced130,	131,	132,	133.	The	typical	primary	CD8	T	cell	response	following	an	exposure	to	a	
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rapidly-cleared	antigen	as	seen	in	acute	infection	or	vaccination	can	be	divided	into	three	
phases:	(1)	an	expansion	phase,	characterized	by	activation	and	rapid	expansion	of	antigen-
specific	naïve	cells	into	effector	T	cells,	that	mediate	antigen	clearance;	followed	by	(2)	a	
contraction	phase,	in	which	approximately	90-95%	of	the	effector	CD8	T-cell	population	
undergo	apoptotic	cell	death,	leaving	a	small	subset	of	cell	that	go	through	the	(3)	memory	
differentiation	and	maintenance	phase,	in	which	stable,	polyfunctional	memory	CD8	T	cells	are	
maintained	via	homeostatic	proliferation134.	In	contrast,	persistent	antigen	stimulation	as	seen	
in	chronic	infection	in	mice	usually	leads	to	a	much	delayed	CD8	T	cell	contraction	phase	due	to	
antigen	persistence135.	It	has	been	shown	that	Ad5	immunization	leads	to	a	protracted	CD8	T	
cell	expansion	phase,	with	little	or	no	immune	contraction23,	81,	83,	84,	136.	In	our	study,	we	
showed	that	reducing	the	dose	of	Ad5	leads	to	a	more	pronounced	CD8	T	cell	contraction,	
similar	to	what	is	observed	following	immunization	with	alternative	serotype	Ad	vectors23,	81,	
MVA136,	or	following	an	acute	LCMV	infection137.	It	has	also	been	shown	that	the	duration	and	
persistence	of	antigenic	stimulation	is	dependent	on	the	Ad	vector	type	and	vector	dosage138.	
Although,	our	study	did	not	directly	assess	the	persistence	of	antigen	stimulation	following	
administration	of	different	doses	of	Ad5	vector,	we	hypothesize	that	the	improved	contraction	
we	observed	is	likely	due	to	a	reduction	in	amount	and	duration	of	antigen	expression	following	
low	dose	Ad5	immunization.		
Using	the	LCMV	mice	infection	model,	Joshi	et	al.	showed	that	effector	CD8	T	cells	can	be	
differentiated	into	SLEC	(CD127-KLRG1+)	and	MPEC	(CD127+KLRG1-)	populations	based	on	
expression	of	both	CD127	and	KLRG1	on	CD8+	T	cells114.	SLECs,	which	are	short	lived,	
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predominate	in	situations	of	antigen	persistence	but	undergo	significant	apoptosis	following	
antigen	clearance,	while	MPECs	developed	into	long-lived,	self-renewing	memory	CD8	T	cells.	In	
addition,	compared	to	SLECs,	MPECs	are	more	“functionally	mature”	with	an	increased	capacity	
to	proliferate	and	produce	IL-2	in	addition	to	IFNγ	and	TNF-α,	i.e.	greater	polyfunctionality.	We	
observed	that	a	low	dose	Ad5	immunization	leads	to	a	higher	proportion	of	CD8	T	cells	
differentiating	into	the	relatively	more	stable	MPECs	with	improved	polyfunctionality	(IFN-
γ+TNF-α+IL-2+).	This	improved	memory	differentiation	probably	resulted	in	the	enhanced	recall	
expansion	we	observed	following	heterologous	boosting	with	Ad35	(Fig,	2C-D)	or	MVA	(data	
not	shown).	We	also	showed	that	there	is	a	lower	per	cell	PD-1	expression	following	low	dose	
Ad5	immunization	compared	to	high	dose	Ad5.	Since	the	duration	of	antigenic	stimulation	is	
also	known	to	affect	the	expression	of	these	markers139,	140,	141,	142,	we	speculate	that	the	overall	
improvement	seen	with	lower	dose	of	Ad5	is	a	result	of	reduced	antigen	persistence.		
The	route	of	administration	of	Ad5	vector	immunization	may	also	influence	the	immune	
response	elicited,	such	that	intravenous	administration	leads	to	a	more	dysfunctional	immune	
response	compared	to	other	modes	of	administration.	Intravenous	injection	of	adenovirus	5	
leads	to	a	rapid	accumulation	of	the	virus	within	the	liver	due	to	its	hepatic	tropism143.	High	
viral	load	in	the	liver	leads	to	T	cell	exhaustion	and	depletion	of	antigen-specific	cytotoxic	T	
lymphocytes144,	145.	Therefore,	another	plausible	explanation	for	Ad5-immune	dysfunction	is	
that	high	dose	Ad5	immunization	results	in	a	significantly	higher	number	of	viral	particles	
migrating	to	the	liver,	where	they	can	contribute	to	the	development	of	dysfunctional	T	cells.	
This	possibility	needs	to	be	further	explored.	
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Exhausted	T	cells	seen	during	chronic	infections	such	as	HIV,	malaria,	HCV,	and	HBV	in	
humans,	or	chronic	LCMV	infection	in	mice	are	known	to	up-regulate	immunoinhibitory	
receptors	such	as	PD-1.	The	PD-1/PD-L1	signaling	pathway	is	involved	in	normal	immune	
responses,	and	several	regulatory	processes	ranging	from	tolerance	to	T	cell	exhaustion.	The	
significant	reduction	in	PD-1	expression	following	low	dose	Ad5	immunization,	coupled	with	the	
improved	recall	response	suggests	that	the	higher	PD-1	expression	may	be	mediating	the	
impaired	recall	response	associated	with	high-dose	Ad5.	Indeed,	Fuse	et	el.	showed	that	
“helpless“	CD8	T	cells	(without	CD4	T	cells	help)	highly	express	PD-1	and	exhibit	improve	recall	
response	following	PD-1	blockade102.	Similarly,	we	observed	that	blocking	PD-1	signaling	via	an	
in	vivo	PD-L1	blockade	led	to	an	improved	memory	recall	following	secondary	antigen	
encounter.	Interestingly,	this	observation	was	seen	only	when	the	blockade	was	done	at	the	
time	of	boosting,	with	no	effect	seen	with	PD-L1	blockade	at	the	time	of	priming	with	Ad5.	The	
failure	of	PD-L1	blockade	at	prime	could	be	due	to	the	need	for	an	“exhausted”	state	
(upregulation	of	PD-1)	to	be	established	before	the	effect	of	blocking	PD-L1:PD-1	interaction	
can	be	seen.	PD-L1	is	expressed	on	T	cells,	B	cells,	DCs,	and	is	up-regulated	following	IFN-γ	
treatment.	However,	there	was	no	differential	up-regulation	of	PD-L1	on	transduced	DC	in	the	
draining	lymph	node	following	Ad5	immunization	compared	to	Ad26	immunization	(Penaloza-
MacMaster,	P,	et	al,unpublished	data).	Our	data	therefore	suggest	that	the	intrinsic	PD-1	
signaling	may	be	partly	mediating	Ad-5	induced	immune	dysfunction.		
		 Tregs	play	a	major	role	in	maintaining	peripheral	tolerance,	in	addition	to	controlling	
immune	response	to	infections.	Their	role	in	maintaining	T	cells	in	an	exhausted	state	was	
		
43	
demonstrated	by	the	striking	rescue	of	exhausted	T	cells	following	Tregs	ablation.	In	a	cancer	
vaccine	model,	vaccination	with	alphavirus	vector	expressing	human	papillomavirus	(HPV)	type	
16	peptides	did	not	result	in	changes	in	the	number	and/or	activity	of	Tregs,	and	the	depletion	
of	Tregs	did	not	improve	the	efficacy	of	this	vaccine	against	tumours146.		However,	alphavirus	
vector	elicited	immune	responses	are	not	known	to	exhibit	immune	exhaustion.	With	CD8	T	
cells	induced	by	Ad5	exhibiting	a	partial	exhausted	phenotype	and	the	significant	role	Tregs	
play	in	maintaining	exhausted	T	cells,	it	is	possible	that	regulatory	T	cells	may	be	contributing	to	
the	impaired	T	cells	response	seen	following	Ad5	immunization.	Our	study	did	not	find	any	
difference	in	the	magnitude	and	suppressive	function	of	Tregs	following	Ad5	or	Ad26	
immunization.	We	chose	Ad26	as	control	because	it	does	not	elicit	a	dysfunctional	immune	
response	like	Ad523.	Although	further	studies	are	needed	to	completely	exclude	a	role	for	Tregs,	
our	data	provide	a	hint	that	the	regulatory	T	cell	may	not	play	a	significant	role	in	modulating	
Ad5-induced	immune	dysfunction.		
In	summary,	our	data	suggest	that	antigenic	stimulation	and	the	immunoinhibitory	
receptor	PD-1	plays	a	significant	role	in	modulating	Ad5-induced	immune	dysfunction.	The	
absence	of	an	effect	of	Ad5	immunization	on	Tregs	and	the	expression	of	PD-L1	on	antigen	
presenting	cells	also	suggest	that	the	immune	dysfunction	seen	with	Ad5	is	primarily	a	CD8	
intrinsic	phenomenon.	Although	pre-existing	vector	immunity	may	impede	the	use	of	Ad5	in	
future	clinical	vaccine	trials,	particularly	in	regions	of	high	seroprevalence,	the	mechanistic	
implication	of	the	data	shown	here	will	be	useful	in	selecting	and	testing	other	similar	viral	
vectors	for	future	vaccine	development.				
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3.1 Limitations	
The	immunogenicity	data	presented	in	this	study	were	acquired	by	assessing	immune	
responses	longitudinally	in	blood,	with	very	few	evaluation	of	the	responses	in	tissues.	It	is	
possible	that	the	immune	response	in	blood	may	slightly	differ	from	those	of	tissues	-	both	
lymphoid	and	non	lymphoid	tissues.	The	decision	to	focus	on	blood	was	due	to	the	need	to	
evaluate	memory	recall.	The	assessment	of	tissue	immune	response	prior	of	boost	will	require	
sacrificing	the	animal	which	will	preclude	an	internally	controlled	evaluation	of	the	magnitude	
of	immune	expansion.		In	addition,	the	experiments	reported	here	were	all	carried	out	in	mice.	
Whether	similar	findings	will	be	seen	in	non-human	primates	and	humans	is	yet	to	be	
determined.		
3.2 Future	directions	
The	improved	immune	response	seen	following	immunization	with	lower	dose	Ad5	may	be	
due	to	an	accelerated	antigen	clearance.	Future	experiments	may	utilize	in	vivo	imaging	studies,	
transgene	transcript	PCR	and	measurement	of	in	vivo	proliferation	of	adoptively	transfer	
antigen-specific	T	cells	to	compare	the	duration	of	transgene	expression	following	low	dose	and	
high	dose	Ad5	immunization,	and	comparing	Ad5	to	other	serotype	adenovirus	such	as	Ad26.	In	
our	study,	the	magnitude	of	transgene-specific	memory	CD8	T	cells	was	significantly	higher	in	
high	dose	Ad5-primed	mice	compared	to	low	dose	Ad5-primed	mice	prior	to	heterologous	
boost	because	of	the	profound	immune	contraction	seen	with	low	dose	Ad5	immunization.	
Future	adoptive	transfer	experiments	will	normalize	for	the	number	of	antigen	specific	memory	
cells	transferred	into	congenically	distinct	mice	before	heterologous	boost.	Future	experiments	
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will	also	help	to	determine	if	Ad5-induced	dysfunction	is	truly	a	CD8	T	cell	intrinsic	
phenomenon	or	whether	it	is	due	to	differences	in	the	immune	environment.	In	addition,	an	
assessment	of	the	amount	of	vector	reaching	the	liver	following	intramuscular	immunization	
with	high	dose	Ad5,	and	the	degree	of	hepatotoxicity,	if	any,	will	help	to	determine	if	liver	
sequestration	of	Ad5	vector	contributes	to	the	impaired	response.		
We	show	here	that	PD-L1	blockade	leads	to	an	improvement	in	immune	recall	following	
heterologous	boost	even	though	PD-L1	expression	is	not	differentially	up-regulated	on	antigen	
presenting	cells	following	Ad5	compared	to	Ad26	immunization.	It	is	therefore	important	to	
determine	if	treatment	with	PD-1	blocking	antibody	will	lead	to	a	similar	improvement	in	
immune	expansion.	In	addition,	future	studies	should	also	assess	if	a	combination	of	dose	
reduction	and	PD-1	signaling	blockade	will	lead	to	a	synergistic	improvement	in	immune	recall.	
The	effect	of	low	dose	Ad5	immunization	on	the	expression	of	other	immmunoinhibitory	
molecules	such	as	Tim-3	and	CTLA-4,	and	whether	blockade	of	these	receptors	will	similarly	
lead	to	immune	rescue	should	also	be	determined.			
Our	preliminary	findings	also	suggest	that	Tregs	may	not	play	a	critical	role	in	modulating	
Ad5-induced	immune	dysfunction.	Future	experiment	should	determine	the	effect	of	
immunization	on	Treg	magnitude	and	function	at	later	(memory)	time	points.	It	is	also	
important	to	determine	more	conclusively	the	role	of	Tregs	by	assessing	the	effect	of	Treg	
depletion	using	the	FoxP3DTR	mouse	model.	Finally,	and	most	importantly,	future	research	
should	assess	the	protective	efficacy	of	the	improved	immune	response	observed	following	low	
dose	Ad5	immunization	and	PD-1	signaling	blockade	as	the	ultimate	goal	of	vaccines	is	to	
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protect	against	pathogens	or	significantly	lessen	disease	burden.		
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